Abstract:Twenty-eight patients with a median age of 38 (15~54) years received allogeneic peripheral blood stem cell transplantation (allo-HSCT). Diagnoses included AML (n=7), ALL (n=2), CML (n=13), MM (n=4), MDS (n=1) and advanced ovarian cancer (n=1). Thirteen patients of them had progressive diseases. Myeloablative conditioning was given to 12 patients and non-myeloablative conditioning to 16 patients. FACS sorted granulocytes, T lymphocytes, B lymphocytes and NK cells from peripheral blood of all patients were analyzed for PCR amplification of short tandem repeats. The purity of sorted cells was above 96%. On day 7 posttransplant, the chimerism of NK cells was the highest in 88.5% patients, indicating that NK cells were the earliest engrafting cells. The subpopulations of granulocytes, B lymphocytes and NK cells reached complete chimerism (CC) on a median of day 14 posttransplant, while T lymphocytes were the latest subpopulation to reach CC in both myeloablative and non-myeloablative transplant on a median of day 21 and day 28 posttransplant, respectively. Seven patients with myeloid malignancy had molecular omen of graft rejection or disease relapse. Three patients of them had chimerism of donor T cells shifting from CC to MC only, while other subpopulation of cells remained CC. T cell chimerism in 2 patients of them remained lowest level among all subpopulation of cells. Recipient T cells had decreasing MC in 5 cases after discontinuance of immunosuppressant and donor lymphocyte infusion, 3 of them achieved CC again. Eight cases developed acute GVHD in 19 stable CC patients. Seven of them had GVHD after CC was achieved by all cell subsets. None of the patients in unstable CC group developed GVHD before they had graft rejection or relapse. The rate of acute GVHD of CC group was higher than MC group(χ2=4.25, P<0.05). We conclude that donor T lymphocytes are the earliest subpopulation of cells to subside during the course of graft rejection and disease relapse in myeloid malignancy. Patients responding to adjustment of immunosuppressants and/or DLI could achieve CC of T lymphocyte fraction again. CC of T lymphocyte could be a marker of stable engraftment of donor cells. Progressive MC of T cell is the omen of graft rejection and disease relapse. Immunosuppressant dosage should be adjusted according to T lymphocyte chimerism for different patients. GVHD prevention should be preferred in patients who reach CC in T cell fraction in one month after transplant. Therefore we suggest the patients might be given higher dose and longer period of immunosuppressants in 3 months posttransplant. In order to promote the engraftment of donor cell and avoid disease recurrence, the immunosuppressants might be tapered in the patients who do not reach CC in T cell fraction in one month after transplant and the patients with progressive MC in T cell.

[Analysis of Hematopoietic Chimerism after Non-Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation].

Quantitative Assessment Of Hematopoietic Chimerism After Allogeneic Nonmyeloalblative Stem Cell Transplantation.

Application of sequential and quantitative monitoring of chimerism in allogeneic hematopoietic stem cell transplantation]

SEMI-QUANTITATIVE ANALYSIS OF CHIMERISM AFTER NON-MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION BY STR-PCR

Sequential and quantitative analysis of chimerism after non-myeloablative stem cell transplantation]

Serial and quantitative analysis of lymphoid and myeloid chimerism after allogeneic peripheral blood stem cell transplantation

[Clinical Significance of Dynamic Monitoring of Cell Chimerism Following Allogeneic Hematopoietic Stem Cell Transplantation].

An analysis of leukocyte subsets chimerism following allogeneic peripheral blood stem cell transplantation]

Semi-quantitative analysis of chimerism after allogeneic stem cell transplantation using STR-PCR

Quantitative Chimerism Kinetics in Relapsed Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplantation.

Prospects and Potential for Chimerism Analysis after Allogeneic Hematopoietic Stem Cell Transplantation

Chimerism Status is Correlated to Acute Graft-Versus-host Disease after Allogeneic Stem Cell Transplantation

Effects of chimerism on the mice heart transplanted survival with the bone marrow infusion.

[Quantitative Analysis of Donor Chimerism in Adoptive Immunotherapy Following Allogeneic Hematopoietic Stem Cell Transplantation].

Engraftment and Measurable Residual Disease Monitoring after Hematopoietic Stem Cell Transplantation: Comparison of Two Chimerism Test Strategies, Next-Generation Sequencing versus a Combination of Short-Tandem Repeats and Quantitative PCR

Utility of Next-Generation Sequencing-Based Chimerism Analysis for Early Relapse Prediction following Allogenic Hematopoietic Cell Transplantation

Donor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation.

Quantitative Monitoring of Multi-donor Chimerism after Multi-donor Allogeneic Hematopoietic Stem Cell Transplantation

Individualized immunotherapy based on blood cell chimerism after allogeneic hematopoietic stem cell transplantation

Prediction, Management, and Prognosis of Mixed Chimerism after Hematopoietic Stem Cell Transplantation in Transfusion-Dependent Pediatric Thalassemia Patients

Adjustment Of Immonosuppressants Based On T Lymphocyte Chimerism Following Allogeneic Hematopoietic Stem Cell Transplantation.